BMS-582949: crystalline form of a p38alpha inhibitor? WO2008079857.
The p38 kinases have long been recognized as potentially valuable targets in the development of novel anti-inflammatory therapies. An application claiming a single crystalline form of N-(5-(cyclopropylcarbamoyl)-2-methylphenyl)-5-methyl-1-(3-(trifluoromethyl)pyridin-2-yl)-1H-pyrazole-4-carboxamide and its therapeutic use for the treatment of inflammatory diseases including rheumatoid arthritis, psoriasis and atherosclerosis points to the claimed compound being a development compound. The available evidence suggests that the compound could be BMS-582949, a compound in Phase II studies for the treatment of rheumatoid arthritis, psoriasis and atherosclerosis.
Norman
Peter
P
Norman Consulting, Burnham, Buckinghamshire, SL1 8JW, UK. peter.norman2@btinternet.com
D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D010330:Patents as Topic; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D011720:Pyrazoles / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*
C544524:N-(5-(cyclopropylcarbamoyl)-2-methylphenyl)-5-methyl-1-(3-(trifluoromethyl)pyridin-2-yl)-1H-pyrazole-4-carboxamide; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D048051:p38 Mitogen-Activated Protein Kinases